TRCT
ESLA icon

Tower Research Capital (TRC)’s Estrella Immunopharma ESLA Stock Holding History

Tower Research Capital (TRC)’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44K Sell
3,308
-1,551
-32% -$2.03K ﹤0.01% 4534
2026
Q1 		$5.15K Buy
+4,859
New +$5.58K ﹤0.01% 4137
2025
Q4 		– Sell
-4,015
Closed -$4.62K – 5260
2025
Q3 		$4.62K Sell
4,015
-578
-13% -$555 ﹤0.01% 4322
2025
Q2 		$4.41K Sell
4,593
-1,053
-19% -$1.02K ﹤0.01% 4332
2025
Q1 		$5.23K Buy
5,646
+1,858
+49% +$2.04K ﹤0.01% 4141
2024
Q4 		$4.55K Sell
3,788
-1,940
-34% -$1.96K ﹤0.01% 4443
2024
Q3 		$6.64K Sell
5,728
-1,423
-20% -$1.83K ﹤0.01% 4122
2024
Q2 		$7.51K Buy
7,151
+1,580
+28% +$1.62K ﹤0.01% 4459
2024
Q1 		$6.91K Buy
5,571
+4,939
+781% +$5.54K ﹤0.01% 4298
2023
Q4 		$702 Buy
+632
New +$955 ﹤0.01% 5508

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s ESLA Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Estrella Immunopharma (ESLA) stake by 32% in Q2 2026, selling an estimated $2.03K and leaving 3,308 shares worth $3.44K. The position accounts for ﹤0.01% of the portfolio, ranked #4534.

Tower Research Capital (TRC) first reported a position in ESLA in Q4 2023 and has held it in 10 quarters since. The position peaked at $7.51K in Q2 2024. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Tower Research Capital (TRC) held 3,308 shares of Estrella Immunopharma worth $3.44K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,551 Estrella Immunopharma shares in Q2 2026, an estimated $2.03K.
  • Estrella Immunopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4534 holding.
  • Tower Research Capital (TRC) first reported a position in Estrella Immunopharma in Q4 2023 and has held it in 10 quarters since.
  • Tower Research Capital (TRC)'s Estrella Immunopharma position peaked at $7.51K in Q2 2024.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.